Immuno-Oncology Frontiers World 2019 is a conference that covers topics such as:
- Collaboration strategies: what do investors and big pharma want to see from biotech and academia in order to invest/partner?
- The value of immuno-oncology RD assets and how these therapies are shaping current and future oncology RD pipelines
- Overcoming hurdles in translation: what progress has been made in developing more informative pre-clinical models to provide real insights for the clinic?
- What will European market access strategy for CAR T cell therapies and combination therapies look like?
- The use of predictive biomarkers and their role in predicting patient response rates in the clinic
- Key scientific advancements from emerging immuno-oncology biotechs including coverage of oncolytic virus therapies, cancer vaccines, next-generation cellular immunotherapies, the tumour microenvironment, combination therapies and next-generation checkpoint inhibitors
- Clinical endpoints: how to ensure relevant/alternative surrogate endpoints are incorporated into immuno-oncology studies?
- The future for a busy immuno-oncology combination therapy marketplace - defining the clinical and commercial approaches that will be used when combining multiple therapies
- Highlighting key recent and forthcoming areas of EU regulatory guideline and legislation development what is need to know for the worlds immuno-oncology industry leaders?
- CAR T immunotherapies or bispecific antibodies?
Immuno-Oncology Frontiers World 2019 brings together:
- VP Immunotherapy
- Venture Partner
- Cheif Scientific Officer
- Chief Executive Officer
- VP, Head of Translational Biomarkers
- VP & Managing Director
- Senior Director, Translational Oncology
- Programme Director, Scientific Affairs
- Senior Pharmaceutical Analyst and European Head
- Managing Director, European & Asian Operations
- Senior Director, Global Head Search & Evaluation Oncology
- VP, Head Search & Evaluation, Business Development